Navigation Links
GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
Date:12/5/2008

is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filin
'/>"/>

SOURCE GenVec, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
2. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
3. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
4. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
5. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
6. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
7. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
8. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
9. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
10. GeneThera Announces it is Set to Begin Commercial Testing for Johnes Disease as Soon as January, 2009.
11. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  Caris Life Sciences® today ... targeting specific pathways may have potentially significant benefit in ... study results were highlighted today in an oral presentation ... Oncology (SGO) 2015 Annual Meeting on Women,s Cancer in ... study is one of four presented at the annual ...
(Date:3/30/2015)... 2015 NiQ Health, "the ... the high level interface capabilities of their CarePlus™ ... The partnership between CarePlus™ and ClinicAll ... allows patients to choose the most appropriate alarm ... The advanced functionality of CarePlus™ allows patient alarms ...
(Date:3/30/2015)... Calif. , March 30, 2015 ... that it has initiated a multi-dose Phase 1 ... the lead molecule in DURECT,s Epigenomic Regulator Program.  ... (NCE) that may have broad applicability in metabolic ... and nonalcoholic steatohepatitis (NASH).  It may also play ...
Breaking Medicine Technology:Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 2Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 3Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 4NiQ Health Announces CarePlus(TM) Integration with ClinicAll 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4
... Neusoft Corporation ("Neusoft", 600718.SH), a leading IT solution ... its wholly-owned subsidiary Neusoft Europe Inc. ("Neusoft Europe") ... Systems Ltd. ("Aerotel"), a leading global manufacturer of ... solutions based in Israel, under which Neusoft Europe ...
... (NYSE: HSP ), a global specialty pharmaceutical and ... has authorized the repurchase of up to $1 billion of ... underscores our continued belief and optimism in Hospira,s long-term growth ... our shareholders," said F. Michael Ball, chief executive officer. "The ...
Cached Medicine Technology:Neusoft to Invest in Israeli Medical Solutions Company for Accelerating Expansion in Global Healthcare Service Market 2Hospira Board Authorizes $1 Billion Share Repurchase Program 2
(Date:3/31/2015)... Pass, OR (PRWEB) March 31, 2015 ... enthusiasts, late May to mid-June are anxiously awaited. After ... elevation treks, that’s when the winter snowpack in the ... and backers enthusiasts to access the high trails. The ... radio host Sharon Kleyne, was very different. For the ...
(Date:3/31/2015)... March 31, 2015 According to data ... start their own businesses fail within the first 18 ... up to change those numbers for the better. ... based out of the Mahoning Valley in Ohio. YBI ... by offering clients guidance on topics such as management ...
(Date:3/31/2015)... NYC based chiropractor Dr. Steven Shoshany, recently ... is proud to offer an improved and expanded use of ... able to offer percussive soft tissue treatment for ... able to offer full body Active Release Technique treatment and ... he is now also able to offer percussive therapy for ...
(Date:3/31/2015)... Jacksonville, FL (PRWEB) March 31, 2015 ... now see Drivable Grass in action and ... just finished installation of a display plot of ... Street. , Drivable Grass is a permeable concrete ... stylish alternative to asphalt and concrete pavement, Drivable Grass ...
(Date:3/31/2015)... TX (PRWEB) March 31, 2015 ... independent freestanding emergency rooms in the United States, announced ... April. , “I am pleased to announce that ... Worth metroplex in Haslet,” said Dr. James M. Muzzarelli, ... , First Choice Emergency Room is revolutionizing the delivery ...
Breaking Medicine News(10 mins):Health News:2014-15 winter drought offers unique opportunity for Oregon and California hikers and backpackers reports fresh water advocate 2Health News:2014-15 winter drought offers unique opportunity for Oregon and California hikers and backpackers reports fresh water advocate 3Health News:Giving a Leg Up to the Start-ups: PeopleKeys Partners with Youngstown Business Incubator to Provide Support Services to Start-up Companies 2Health News:Giving a Leg Up to the Start-ups: PeopleKeys Partners with Youngstown Business Incubator to Provide Support Services to Start-up Companies 3Health News:NYC Chiropractor Dr Steven Shoshany Expands Percussive Massage Offering 2Health News:NYC Chiropractor Dr Steven Shoshany Expands Percussive Massage Offering 3Health News:Super-Sod Recently Completed a Drivable Grass Permeable Paver Demo at their Jacksonville Store 2Health News:First Choice Emergency Room to Open New Facility in Haslet, Texas 2
... Fries are out of the pan into the fire itself, ... recently enforced Government directives to disclose levels of trans fats ... test levels of trans fat in french fries.// The tests ... contain one third more ( 8 grammes as against earlier ...
... has been reported from a chicken farm located in the ... monitored and is believed to be under control, according to ... 15, 000 chickens in a farm (Yijing township), confirmed to ... to the above situation, a special team to combat spread ...
... The largest ever high blood pressure clinical trial is ... of controlling high blood pressure. // This is a ... Heart Attack Trial (ALLHAT) and is being launched in ... (NHBPEP). ,The ALLHAT blood pressure study ...
... Heart Disease (IHD) which is also called the Coronary Artery ... upon whether it is a man or woman. The blood ... and where Western countries are concerned, this is quite a ... for chest pain, diagnosticians typically look for an obstructive lesion ...
... to Kenya by the World Bank for HIV/AIDS education and ... it has been delayed due to some allegations pertaining to ... against the Kenyan government, the SAPA/Mail & Guardian reports (SAPA/Mail ... of Health in February 2005 it had failed to distribute ...
... of the Journal of Periodontology, says that chronic periodontal ... pregnancy. // The results of the study also indicate ... compared to women who do not have preeclampsia. ... the preeclamptic group by almost 64 percent than the ...
Cached Medicine News:Health News:Diuretics More Effective In Controlling High Blood Pressure 2Health News:Gum Disease Associated With Increased Risk of Preeclampsia 2
... Mandibular Immobilizer) A completely adjustable cervical ... hypertension positioning and immobilization. Offers a ... collar and a halo-type brace.,Mandibular and ... chin plate allows for patient eating ...
... Wrap® Economy Universal Cervical ... with synthtic white stockinette ... for flexion or extension. ... air dry. 3"H.,Universal size ...
... for use for lightweight padding. It can ... to line braces, prosthetics, orthotics and sports ... vibration and conforms to all body contours, ... is a 2mm thick gel sheet with ...
... patient need and comfort in mind, ... of products effectively address a variety ... frame attachment provides optimal post-operative support, ... superior support for patient maintenance and ...
Medicine Products: